Tag - PHGE

Developments

BiomX reports update on trial of BX004 in CF

BiomX (NYSE American: PHGE) has announced that the FDA is continuing its evaluation of the nebulizer device used for drug administration in the company’s Phase 2b trial of BX004 in patients with cystic fibrosis (CF)...

November 26, 2025

Developments

BiomX doses first patient in Phase 2b trial of BX004 in CF

BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...

July 15, 2025

Markets

HCW starts BiomX at buy; PT $20

H.C. Wainwright initiated coverage of BiomX (NYSE American:PHGE) with a “buy” rating and $20 price target. The stock closed at $5.90 on Dec 4. “BiomX is one of the leaders in the development of bacteriophage (phage)...

December 7, 2020

Tag - PHGE

BiomX reports update on trial of BX004 in CF

BiomX doses first patient in Phase 2b trial of BX004 in CF

HCW starts BiomX at buy; PT $20

Subscribe